NHS Greater Glasgow and Clyde awarded "Gene testing and reporting for Ovarian cancer specimens" to Myriad Genetics, with a value of £363,000 (19 November 2026).
NHS Greater Glasgow and Clyde, Laboratory Genetics requires an end-to-end diagnostic service for FFPE block processing, DNA based Homologous Repair Deficiency (HRD) and BRCA1 and BRCA2 gene testing and reporting for Ovarian cancer specimens. This service is required for approximately 200 tests per annum and the service must be available by 1st December 2026.
A weekly round-up of new UK public sector contracts. No spam, unsubscribe any time.